Other Comprehensive Income (Loss)
Regeneron Pharmaceuticals Other Comprehensive Income (Loss) decreased by 22.4% to $661.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 21.8%, from $845.70M to $661.60M. Over 4 years (FY 2021 to FY 2025), Other Comprehensive Income (Loss) shows a downward trend with a -13.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
A large positive value suggests favorable currency or market movements, while a large negative value indicates potential future volatility in equity.
Detailed definition
This represents the aggregate of all items of other comprehensive income or loss, which are excluded from net income und...
Peer comparison
Standardized across all public companies under GAAP/IFRS reporting requirements.
tmusz_other_comprehensive_income_lossHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.10B | $1.63B | $2.19B | $829.60M | $798.40M | $1.26B | $1.23B | $875.00M | $952.30M | $1.03B | $1.26B | $725.70M | $1.44B | $1.47B | $849.60M | $845.70M | $1.42B | $1.48B | $853.10M | $661.60M |
| QoQ Change | — | -47.5% | +34.9% | -62.2% | -3.8% | +58.4% | -2.5% | -29.1% | +8.8% | +8.0% | +22.0% | -42.2% | +98.4% | +2.2% | -42.2% | -0.5% | +67.3% | +4.3% | -42.2% | -22.4% |
| YoY Change | — | — | — | — | -74.2% | -22.2% | -43.8% | +5.5% | +19.3% | -18.6% | +1.8% | -17.1% | +51.2% | +43.0% | -32.3% | +16.5% | -1.7% | +0.4% | +0.4% | -21.8% |
Other Comprehensive Income (Loss) at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's other comprehensive income (loss)?
- Regeneron Pharmaceuticals (REGN) reported other comprehensive income (loss) of $661.60M in Q1 2026.
- How has Regeneron Pharmaceuticals's other comprehensive income (loss) changed year-over-year?
- Regeneron Pharmaceuticals's other comprehensive income (loss) decreased by 21.8% year-over-year, from $845.70M to $661.60M.
- What is the long-term trend for Regeneron Pharmaceuticals's other comprehensive income (loss)?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's other comprehensive income (loss) has grown at a -13.0% compound annual growth rate (CAGR), from $8.02B to $4.59B.
- What does other comprehensive income (loss) mean?
- The total of all gains and losses that are recorded directly in equity rather than through the income statement.